EMERGENT BIOSOLUTIONS INC (EBS)
US29089Q1058 - Common Stock
Taking everything into account, EBS scores 3 out of 10 in our fundamental rating. EBS was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of EBS have multiple concerns. EBS is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year EBS has reported negative net income.
In the past year EBS had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: EBS reported negative net income in multiple years.
In multiple years EBS reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of -14.13%, EBS belongs to the best of the industry, outperforming 84.42% of the companies in the same industry.
Looking at the Return On Equity, with a value of -41.07%, EBS is in the better half of the industry, outperforming 72.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.13% | ||
| ROE | -41.07% | ||
| ROIC | N/A |
ROA(3y)-13.66%
ROA(5y)-5.61%
ROE(3y)-39.61%
ROE(5y)-18.54%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EBS has a Gross Margin of 33.51%. This is in the better half of the industry: EBS outperforms 75.40% of its industry peers.
In the last couple of years the Gross Margin of EBS has declined.
The Profit Margin and Operating Margin are not available for EBS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.51% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.37%
GM growth 5Y-11.03%
2. Health
2.1 Basic Checks
EBS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EBS has more shares outstanding
EBS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for EBS is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.01, we must say that EBS is in the distress zone and has some risk of bankruptcy.
EBS's Altman-Z score of 1.01 is fine compared to the rest of the industry. EBS outperforms 66.19% of its industry peers.
The Debt to FCF ratio of EBS is 4.80, which is a neutral value as it means it would take EBS, 4.80 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.80, EBS belongs to the top of the industry, outperforming 93.81% of the companies in the same industry.
A Debt/Equity ratio of 1.30 is on the high side and indicates that EBS has dependencies on debt financing.
EBS has a worse Debt to Equity ratio (1.30) than 80.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.3 | ||
| Debt/FCF | 4.8 | ||
| Altman-Z | 1.01 |
ROIC/WACCN/A
WACC8.37%
2.3 Liquidity
A Current Ratio of 2.88 indicates that EBS has no problem at all paying its short term obligations.
The Current ratio of EBS (2.88) is worse than 67.08% of its industry peers.
EBS has a Quick Ratio of 1.47. This is a normal value and indicates that EBS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.47, EBS is doing worse than 81.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.88 | ||
| Quick Ratio | 1.47 |
3. Growth
3.1 Past
EBS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.49%, which is quite impressive.
EBS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -11.27%.
Measured over the past years, EBS shows a small growth in Revenue. The Revenue has been growing by 6.05% on average per year.
EPS 1Y (TTM)77.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%385.42%
Revenue 1Y (TTM)-11.27%
Revenue growth 3Y-12.3%
Revenue growth 5Y6.05%
Sales Q2Q%8.61%
3.2 Future
The Earnings Per Share is expected to grow by 14.79% on average over the next years. This is quite good.
EBS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.20% yearly.
EPS Next Y81.57%
EPS Next 2Y59.72%
EPS Next 3Y33.92%
EPS Next 5Y14.79%
Revenue Next Year3.43%
Revenue Next 2Y2.93%
Revenue Next 3Y-2.51%
Revenue Next 5Y6.2%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for EBS. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 3.12, which indicates a rather cheap valuation of EBS.
99.29% of the companies in the same industry are more expensive than EBS, based on the Price/Forward Earnings ratio.
EBS is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.41, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.12 |
4.2 Price Multiples
EBS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. EBS is cheaper than 99.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.69 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
EBS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as EBS's earnings are expected to grow with 33.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y59.72%
EPS Next 3Y33.92%
5. Dividend
5.1 Amount
EBS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EMERGENT BIOSOLUTIONS INC
NYSE:EBS (1/13/2025, 8:14:57 PM)
After market: 9.635 +0.22 (+2.39%)9.41
-0.47 (-4.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners57.55%
Inst Owner Change0%
Ins Owners1.13%
Ins Owner Change-0.38%
Market Cap509.83M
Analysts74.29
Price Target12.24 (30.07%)
Short Float %13.07%
Short Ratio5.33
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)362.91%
Min EPS beat(2)-143.07%
Max EPS beat(2)868.88%
EPS beat(4)2
Avg EPS beat(4)148.12%
Min EPS beat(4)-301.25%
Max EPS beat(4)868.88%
EPS beat(8)2
Avg EPS beat(8)-73.33%
EPS beat(12)4
Avg EPS beat(12)-233.81%
EPS beat(16)6
Avg EPS beat(16)-184.42%
Revenue beat(2)1
Avg Revenue beat(2)15.25%
Min Revenue beat(2)-2.22%
Max Revenue beat(2)32.73%
Revenue beat(4)2
Avg Revenue beat(4)14.71%
Min Revenue beat(4)-6.7%
Max Revenue beat(4)35.04%
Revenue beat(8)6
Avg Revenue beat(8)18.86%
Revenue beat(12)8
Avg Revenue beat(12)11.59%
Revenue beat(16)9
Avg Revenue beat(16)6.36%
PT rev (1m)0%
PT rev (3m)50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-161.22%
EPS NY rev (1m)0%
EPS NY rev (3m)50.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.83%
Revenue NY rev (1m)-0.36%
Revenue NY rev (3m)-0.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.12 | ||
| P/S | 0.45 | ||
| P/FCF | 3.69 | ||
| P/OCF | 2.99 | ||
| P/B | 1 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.13
EYN/A
EPS(NY)3.02
Fwd EY32.09%
FCF(TTM)2.55
FCFY27.09%
OCF(TTM)3.15
OCFY33.48%
SpS20.77
BVpS9.38
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.13% | ||
| ROE | -41.07% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.51% | ||
| FCFM | 12.27% |
ROA(3y)-13.66%
ROA(5y)-5.61%
ROE(3y)-39.61%
ROE(5y)-18.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.37%
GM growth 5Y-11.03%
F-Score6
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.3 | ||
| Debt/FCF | 4.8 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 29% | ||
| Cap/Sales | 2.9% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.88 | ||
| Quick Ratio | 1.47 | ||
| Altman-Z | 1.01 |
F-Score6
WACC8.37%
ROIC/WACCN/A
Cap/Depr(3y)159.63%
Cap/Depr(5y)139.66%
Cap/Sales(3y)16.79%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%385.42%
EPS Next Y81.57%
EPS Next 2Y59.72%
EPS Next 3Y33.92%
EPS Next 5Y14.79%
Revenue 1Y (TTM)-11.27%
Revenue growth 3Y-12.3%
Revenue growth 5Y6.05%
Sales Q2Q%8.61%
Revenue Next Year3.43%
Revenue Next 2Y2.93%
Revenue Next 3Y-2.51%
Revenue Next 5Y6.2%
EBIT growth 1Y68.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year127.06%
EBIT Next 3Y29.96%
EBIT Next 5Y16.99%
FCF growth 1Y176.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.54%
OCF growth 3YN/A
OCF growth 5YN/A